Add BrightSurf on Google Email

AFM-Telethon, Nobel Laureate Drew Weissman and neuromuscular disease expert James Dowling join forces to develop the next generation of gene therapies

A new two-year research program aims to develop novel delivery systems for gene therapies, specifically targeting muscle fibres and muscle stem cells using lipid nanoparticles. The project will focus on advancing innovative therapies for neuromuscular disorders, including Duchenne muscular dystrophy and dysferlinopathy.

Gene editing is coming for common diseases. Are we ready?

Gene therapies can already change clinical care, but their use in common conditions raises concerns about permanent harm and competition with existing treatments. Cardiologists propose strategies for determining when genomic therapy is justified, including considering the benefits, risks, and long-term safety monitoring.

SourceMichigan Medicine - University of Michigan·JournalJAMA Internal Medicine·TypeCommentary/editorial·DateOct 20, 2026

First-in-human pilot trial for new sickle cell disease gene therapy approach proves quicker, more efficient than industry average

Researchers from Boston Children's Hospital have developed a new gene therapy approach that collects enough stem cells in a single hospital admission, improving turnaround time for genetically altering and infusing cells. The approach has shown long-term stability and safety, with patients not experiencing any adverse effects.

SourceBoston Children's Hospital·JournalBlood·DateAug 25, 2026

Bioinspired nanoparticles deliver gene editing to lower “bad” cholesterol

Researchers developed a bioinspired lipid nanoparticle that delivered gene-editing machinery to the liver, reducing low-density lipoprotein (LDL) cholesterol by over 20% and showing fewer signs of inflammation and toxicity. The nanoparticles also demonstrated positive effects on inflammation and healthy blood flow in cell experiments.

Scientists at UMass Chan Medical School develop microRNA-based gene therapy that halts ALS progression in mice

Researchers at UMass Chan Medical School have developed a microRNA-based gene therapy that suppresses mutant SOD1 production, delaying disease onset by 60 days and extending lifespan by 100 days in mice models of ALS. The therapy, delivered via adeno-associated virus (AAV) vector, preserves motor neurons and maintains neuromuscular con...

SourceUMass Chan Medical School·JournalNature Communications·TypeExperimental study·DateJul 29, 2026

Endocytosis-independent delivery: Bypassing cellular barriers for direct biomolecule translocation into living cells

Emerging non-endocytic delivery strategies enable direct cytosolic delivery of proteins, nucleic acids, and gene-editing tools, providing new opportunities for biomedical therapies. The review discusses their application prospects in gene therapy, macromolecular drug delivery, and cellular engineering.

SourceBiomedical Analysis·JournalBiomedical Analysis·TypeLiterature review·DateJul 24, 2026

New fluorescence-based method for identifying gene editing targets

Researchers developed a novel fluorescent-based method to analyze upstream open reading frames (uORFs) in plant genomes, enabling rapid analysis of gene regulation. The technique simplifies current methods by using intact leaf tissue and fluorescent proteins, reducing sample preparation and consumable materials.

Gene therapy reverses Fragile X deficits in mice

Researchers developed a gene therapy that restored normal brain activity and improved behavior in mice with Fragile X syndrome by replacing the missing FMRP protein. The treatment administered during early development showed significant improvements in cognitive flexibility, social interactions, and probabilistic reversal learning.

SourceUniversity of California - Riverside·JournalMolecular Therapy — Nucleic Acids·TypeExperimental study·DateJun 18, 2026

New therapy may reverse autism-related brain deficits

Researchers identified a promising new strategy for reversing autism-related brain deficits by targeting a specific glycine transporter. The therapy restored NMDA receptor function in mouse models and human brain organoids, improving behavioral abnormalities such as social interaction and repetitive behaviors.

SourceInstitute for Basic Science·JournalNature Communications·TypeExperimental study·DateJun 9, 2026

UMass Chan scientists develop gene editing technology capable of rewriting entire chapters of the genome

Researchers have developed a new gene editing technology called 'prime assembly' that allows efficient insertion of large DNA segments into the human genome. This innovation enables treatment of genetic diseases by replacing entire genes, promising substantial progress in treating conditions with multiple mutations.

SourceUMass Chan Medical School·JournalNature·TypeExperimental study·DateMay 13, 2026

RNA-guided CRISPR system activates gene expression

Researchers have discovered an RNA-guided CRISPR system that can activate genes without cutting DNA, opening up new possibilities for gene regulation and therapeutic strategies. The system uses a strand of RNA as a guide to recruit the cell's transcription machinery, allowing for precise control over gene expression.

SourcePurdue University·JournalNature·DateMar 25, 2026

Gene therapy for Duchenne muscular dystrophy: Genethon confirms two-year efficacy in patients treated with its drug candidate GNT0004 at therapeutic dose in the first phase of its clinical trial

Genethon's GNT0004 gene therapy shows long-term efficacy in patients with Duchenne muscular dystrophy, maintaining clinical efficacy and safety at two years. The trial included 72 boys aged 6-10 with retained walking ability, treated with GNT0004 at a therapeutic dose.

Atamyo Therapeutics presents promising results in the first patients treated with its ATA-200 gene therapy in the clinical trial targeting LGMD-R5 limb-girdle muscular dystrophy

The company's ATA-200 gene therapy has shown safety, pharmacodynamics, and efficacy results in the first patients treated, offering hope for children with LGMD-R5. The therapy delivers a normal copy of the γ-sarcoglycan gene and has been awarded Orphan Drug Designation in the US and Europe.

Nanoparticle-based gene editing could expand treatment options for cystic fibrosis

UCLA researchers have developed a novel gene-editing approach using lipid nanoparticles to deliver a full-length CFTR gene into human airway cells. The study shows promise for treating cystic fibrosis by correcting the underlying genetic mutation, which could lead to more effective and long-term therapies.

SourceUniversity of California - Los Angeles Health Sciences·JournalAdvanced Functional Materials·DateFeb 17, 2026

Gene editing produces plants that are indigestible to pests

Researchers have made significant advances in genetically modified plants that produce alpha-amylase inhibitor proteins, making them indigestible to pests like bedbugs, beetles, weevils, and woodworms. Gene editing techniques, such as CRISPR, offer a promising solution to combat insect pests without compromising human consumption.

New gene-editing tech holds promise for treating complex genetic diseases

Researchers at the University of Texas at Austin have developed a novel gene-editing method that can correct multiple disease-causing mutations simultaneously. This approach uses bacterial retrons to protect the microbes from viral infection and has shown promising results in correcting scoliosis-causing mutations in zebrafish embryos.

SourceUniversity of Texas at Austin·JournalNature Biotechnology·TypeExperimental study·DateOct 23, 2025

Epigenetic reprogramming safely modifies multiple genes in T Cells simultaneously for CAR-T therapies

Researchers create enhanced T cells with improved survival in cancer models by simultaneously modifying multiple genes using CRISPRoff and CRISPRon. The approach overcomes toxicity issues associated with traditional gene editing methods, enabling high cell survival rates and potential for treating various diseases.

SourceArc Institute·JournalNature Biotechnology·TypeExperimental study·DateOct 21, 2025